Within the recent news below, RCHA indicates that they have a key relationship with Wuxi Apptec Biopharmaceutical (WX) which trades on the NYSE that is trading at over $40.00+ per share:
WX:NYSE is where RCHA had competed its GMP clinical batch of RP-323 study drug that was manufactured at the WX:NYSE state-of-the-art facility. RCHA is the company that developed the new formulation and all regulatory required testing methods in 2014, but RCHA transferred the proprietary technology ”successfully” to WX:NYSE for the GMP production of RP-323. This is huge.
Also, WX:NYSE is expected to generated approximately $674 Million in Revenues and to deliver profitability in the area of $1.56 to $1.87 EPS (Earnings Per Share) I bring this point up because I am confident that the due diligence for a company of this magnitude believe this much in RCHA, then I must humble myself and any DD that I think is worthy of passing any kind of negative judgment on this company’s future.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.